Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0167
Release Date: July of 2024
Loading...

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Reference Product: Keytruda

Target: Programmed death-1 (PD-1) receptor

Product Category: Antibody

This product provides basic information on drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab).

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
  • Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for pembrolizumab (Keytruda) biosimilars (prerequisite: access to internet).

This product is delivered on the very same day by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Developed by Merck & Co., the blockbuster therapeutic antibody Keytruda (pembrolizumab) was first approved by the FDA in 2014 to treat several types of cancer. Since getting the initial green light, Keytruda has been approved for new and expanded uses, including melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancers, gastric cancer, cervical cancer, and primary mediastinal B-cell lymphoma. The very recent approval of Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma marks the third endometrial carcinoma indication and the 40th indication overall for KEYTRUDA in the U.S.

Key patents of Keytruda will begin to expire in 2028, opening the door to biosimilar competition. In 2023, Keytruda posted global sales of US$ 25 bln.

Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01

Error: Contact form not found.